Chemical Structure (Vimpat 01)
Vimpat Solution
Product Images NDC 0131-5410
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Vimpat (NDC 0131-5410). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Vimpat 02)
Figure 2 (Vimpat 03)
This document appears to be describing the responder rates of patients taking VINPAT versus Placebo in three studies (2, 3, and 4) with varying doses. The figure shows the proportion of patients in each group, grouped by responder rate. However, the text is incomplete and some characters are unclear, making it difficult to ascertain the full context of the results.*
Principal Display Panel (50 mg Tablet Bottle Label)
Principal Display Panel (100 mg Tablet Bottle Label)
This is a medication called VIMPAT, with the National Drug Code (NDC) 0131-2477-35. Each tablet contains 50 mg of the active ingredient lacosamide. The usual dosage should be determined by consulting the package insert, and each patient receiving this medication must be given a Medication Guide. Other information in the text is not available due to errors.*
Principal Display Panel (150 mg Tablet Bottle Label)
This is a description of a medication with the NDC code 0131-2478-35 which is identified as VIMPAT tablets containing 100mg lacosamide. It is suggested to refer to the package insert for dosage information. The text also includes some unidentifiable characters.*
Principal Display Panel (200 mg Tablet Bottle Label)
Principal Display Panel (Kit Carton)
This is a product description for a medication called VIMPAT, which contains 2 200mg lacosamide tablets. The medication guide and package insert should be consulted for dosage information. It is manufactured by UCB, Inc. and comes in a package of 60 tablets. A Medication Guide must be provided to each patient.*
Principal Display Panel (20 mL Vial Carton)
VIMPAT is an injection medication with a concentration of 200 mg per 20 mL (10 mg per mL). It is an intravenous medication and can only be used with a prescription. The medication comes in 10 single-dose vials. The package insert contains information on the usual dosage. The medication should be stored between 20° to 25°C (68° to 77°F), and excursions between 15° to 30°C (59° to 86°F) are allowed. Inactive ingredients include sodium chloride, hydrochloric acid, and water for injection. The medication is a registered trademark of Harris FRC Corporation under license and is covered by one or more claims of US Patent Re 38,551. No other relevant information is available from the given text.*
Principal Display Panel (465 mL Bottle Label)
This is a medication named VIMPAT (lacosamide) used as an oral solution with a concentration of 10 mg/mL. It is indicated for prescription only and requires attention from the pharmacist. The patient needs to read the 465 mL before taking the drug since each mL contains 10 mg lacosamide. The drug is not suitable for phenylketonurics since it contains phenylalanine. Dosage information can be found inside the package it comes with. The recommended storing temperature is between 20°C to 25°C, and it should not be frozen. After opening the package, the unused product should be discarded seven weeks later. The medication should be kept away from children and dispensed in its original container according to the USP/NF standard. The medication is a registered trademark of Harris FRC Corporation and protected by USS Patent Re 38,551. No further information is available.*
Vimpat 11
This is a medication called Vimpat, with a National Drug Code of 0131-5410-71. It is an oral solution composed of lacosamide with a concentration of 10 mg/mL, and it is only available with a prescription. The usual dosage should be stated in the package insert, and it is recommended to store it between 20°C to 25°C. The bottle must be discarded after seven weeks of opening. Additionally, it contains phenylalanine in a dose of 0.32 mg per 20 mL. Vimpat is a registered trademark covered by a US patent claim. The text also includes instructions for dispensing and administration, along with warnings to keep it out of children's reach. There is a code, PT# CIP70131 CIB71465A, and the background appears to be from the packaging of the medication.*
Vimpat 12
This is a medication called Vimpat, specifically the oral solution form with a concentration of 10 mg/mL. The medication is manufactured for UCB, Inc. Each bottle contains 200 mL of solution. It is important to note that each patient who receives this medication must also receive a Medication Guide. The recommended dosage is not provided on the bottle and the package insert should be consulted. The solution should be stored between 20°C to 25°C (68°F to 77°F), with brief excursions permitted between 15°C to 30°C (59°F to 86°F). Once opened, discard any remaining product after six months. The bottle does not have a coating and should be kept out of reach of children.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
